Amanda Kauffman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda Kauffman has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Aleksandra Uzelac
CReATe Fertility Centre, Toronto, Ontario, Canada
1 shared publication- Andrée Gauthier-Fisher
CReATe Fertility Centre, Toronto, Canada
1 shared publication - Ariel Gorodensky
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
1 shared publication - Avishai Gasner
CReATe Fertility Centre, Toronto, Ontario, Canada
1 shared publication Bram Rochwerg
Department of Medicine McMaster Centre for Transfusion Research, McMaster University Hamilton Ontario Canada
1 shared publication- Brandon A. Wyse
CReATe Fertility Centre, Toronto, Canada
1 shared publication
Latest Publications
- Open Access
- 2 February 2026
- Published by Wiley in Transfusion
- Vol. 66 (3) , 491-506
Exploring the immunomodulatory impacts of blood manufacturing consolidation
Introduction: The immunomodulatory consequences of blood transfusion, known as transfusion‐related immune modulation (TRIM), are often not captured by hemovigilance systems. Changes to blood product manufacturing processes may impact patient outcomes. Design and Methods: We conducted a retrospective study of hospitalized adults (≥18 years) in Hamilton, ON, who received ≥1 red blood cell (RBC) transfusion(s) between 2010 and 2014. Primary outcome was in hospital mortality; TRIM outcomes included respiratory failure, organ dysfunction, and sepsis. We evaluated outcomes before and after the change made by Canadian Blood Services (2012) to consolidate manufacturing of blood products in Ontario. Exclusions included autologous, washed, or deglycerolized RBC transfusions, RBCs manufactured outside select regional sites, or patients who received both pre‐/post‐consolidation RBCs. Data was obtained from the TRUST database. Logistic regression adjusted for key covariates. Results: A total of 9871 pre‐ and 7871 post‐consolidation patients met inclusion criteria. Multivariate analysis demonstrated no change in in‐hospital mortality (odds ratio [OR] 1.00, 95% confidence interval [CI] 0.89–1.14, p = 0.95), respiratory failure (OR 0.83, CI 0.65–1.06, p = 0.14) or organ dysfunction (OR 0.95, 95% CI 0.84–1.08, p = 0.42) comparing post to pre‐consolidation. However, hospital‐onset sepsis was lower post‐consolidation (OR 0.59, 95% CI 0.48–0.73, p < 0.001). Conclusions: Consolidation of blood production in Ontario was not associated with changes in rates of in‐hospital mortality, respiratory failure, or organ dysfunction among transfusion recipients, but may be associated with a lower risk of sepsis. TRIM and the clinical impacts of changes to blood processing require further study.
- 2 February 2026
- Published by Wiley in Transfusion
- Vol. 66 (3) , 491-506
Open AccessExploring the immunomodulatory impacts of blood manufacturing consolidation
Introduction: The immunomodulatory consequences of blood transfusion, known as transfusion‐related immune modulation (TRIM), are often not captured by hemovigilance systems. Changes to blood product manufacturing processes may impact patient outcomes. Design and Methods: We conducted a retrospective study of hospitalized adults (≥18 years) in Hamilton, ON, who received ≥1 red blood cell (RBC) transfusion(s) between 2010 and 2014. Primary outcome was in hospital mortality; TRIM outcomes included respiratory failure, organ dysfunction, and sepsis. We evaluated outcomes before and after the change made by Canadian Blood Services (2012) to consolidate manufacturing of blood products in Ontario. Exclusions included autologous, washed, or deglycerolized RBC transfusions, RBCs manufactured outside select regional sites, or patients who received both pre‐/post‐consolidation RBCs. Data was obtained from the TRUST database. Logistic regression adjusted for key covariates. Results: A total of 9871 pre‐ and 7871 post‐consolidation patients met inclusion criteria. Multivariate analysis demonstrated no change in in‐hospital mortality (odds ratio [OR] 1.00, 95% confidence interval [CI] 0.89–1.14, p = 0.95), respiratory failure (OR 0.83, CI 0.65–1.06, p = 0.14) or organ dysfunction (OR 0.95, 95% CI 0.84–1.08, p = 0.42) comparing post to pre‐consolidation. However, hospital‐onset sepsis was lower post‐consolidation (OR 0.59, 95% CI 0.48–0.73, p < 0.001). Conclusions: Consolidation of blood production in Ontario was not associated with changes in rates of in‐hospital mortality, respiratory failure, or organ dysfunction among transfusion recipients, but may be associated with a lower risk of sepsis. TRIM and the clinical impacts of changes to blood processing require further study.
- Open Access
- 22 November 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 53 (1) , 105420
Effect of prolonged oocyte cryopreservation for >10 years on reproductive outcomes – a systematic review and meta-analysis
- 22 November 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 53 (1) , 105420
Open AccessEffect of prolonged oocyte cryopreservation for >10 years on reproductive outcomes – a systematic review and meta-analysis
- Open Access
- 30 November 2023
- Published by Hindawi Limited in Stem Cells International
- Vol. 2023, 1-20
Human Umbilical Cord Perivascular Cells Prevent Tumor Growth in a Melanoma Tumor-Bearing Mouse Model and Modulate Breast Cancer and Melanoma Cells in a Cell Line-Dependent Manner In Vitro
First trimester (FTM) and term human umbilical cord perivascular cells are promising mesenchymal stromal cell candidates to mitigate side effects of oncotherapy, but their safety for cancer patients remains to be determined. This study was designed to determine if human umbilical cord perivascular cells modulate tumor growth when injected systemically in a tumor-bearing mouse model. Immunodeficient mice-bearing palpable subcutaneous SK-MEL-28 human melanoma tumors were randomized to receive a tail vein injection of three human umbilical cord perivascular cell lines resuspended in hanks buffer saline solution (vehicle) or vehicle only, as a control. Fibroblast cells were included as a cell control in some experiments. Tumor size was monitored weekly and weighed at 3-weeks postinjection. Cell fate and tumor cell proliferation, apoptosis, vascularization as well as tumor-associated immune cells were assessed using immunostaining and flow cytometry. Serum tumor necrosis factor alpha and C-reactive protein levels were measured using enzyme-linked immunosorbent assays. Transwell coculture models were used to study the paracrine effects of multiple lines of human umbilical cord cells on human melanoma cell lines as well as breast cancer cell lines. Systemic administration of FTM and term human umbilical cord perivascular cells, but not fibroblast cells, prevented melanoma tumor growth in a tumor-bearing animal model by modulating tumor cell proliferation and systemic inflammatory mechanisms. Cancer cell- and donor-dependent paracrine effects on cancer cell growth were observed in vitro. Our preclinical studies thus suggest that, with regards to its effects on tumor growth, systemic administration of FTM and term human umbilical cord perivascular cells may be a safe cell therapy to address the side effects of cancer.
- 30 November 2023
- Published by Hindawi Limited in Stem Cells International
- Vol. 2023, 1-20
Open AccessHuman Umbilical Cord Perivascular Cells Prevent Tumor Growth in a Melanoma Tumor-Bearing Mouse Model and Modulate Breast Cancer and Melanoma Cells in a Cell Line-Dependent Manner In Vitro
First trimester (FTM) and term human umbilical cord perivascular cells are promising mesenchymal stromal cell candidates to mitigate side effects of oncotherapy, but their safety for cancer patients remains to be determined. This study was designed to determine if human umbilical cord perivascular cells modulate tumor growth when injected systemically in a tumor-bearing mouse model. Immunodeficient mice-bearing palpable subcutaneous SK-MEL-28 human melanoma tumors were randomized to receive a tail vein injection of three human umbilical cord perivascular cell lines resuspended in hanks buffer saline solution (vehicle) or vehicle only, as a control. Fibroblast cells were included as a cell control in some experiments. Tumor size was monitored weekly and weighed at 3-weeks postinjection. Cell fate and tumor cell proliferation, apoptosis, vascularization as well as tumor-associated immune cells were assessed using immunostaining and flow cytometry. Serum tumor necrosis factor alpha and C-reactive protein levels were measured using enzyme-linked immunosorbent assays. Transwell coculture models were used to study the paracrine effects of multiple lines of human umbilical cord cells on human melanoma cell lines as well as breast cancer cell lines. Systemic administration of FTM and term human umbilical cord perivascular cells, but not fibroblast cells, prevented melanoma tumor growth in a tumor-bearing animal model by modulating tumor cell proliferation and systemic inflammatory mechanisms. Cancer cell- and donor-dependent paracrine effects on cancer cell growth were observed in vitro. Our preclinical studies thus suggest that, with regards to its effects on tumor growth, systemic administration of FTM and term human umbilical cord perivascular cells may be a safe cell therapy to address the side effects of cancer.